210 related articles for article (PubMed ID: 12823911)
41. Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine.
Elborn JS; Henig NR
Expert Opin Pharmacother; 2010 Jun; 11(8):1373-85. PubMed ID: 20426707
[TBL] [Abstract][Full Text] [Related]
42. Clinical studies of rhDNase in moderately and severely affected patients with cystic fibrosis--an overview.
Hodson ME
Respiration; 1995; 62 Suppl 1():29-32. PubMed ID: 7792438
[TBL] [Abstract][Full Text] [Related]
43. Comparison of inhaled mannitol, daily rhDNase and a combination of both in children with cystic fibrosis: a randomised trial.
Minasian C; Wallis C; Metcalfe C; Bush A
Thorax; 2010 Jan; 65(1):51-6. PubMed ID: 19996349
[TBL] [Abstract][Full Text] [Related]
44. [Socioeconomic evaluation of the effect of rhDNase on the cost of treating infections of the respiratory tract in patients with cystic fibrosis].
von der Schulenburg JM; Greiner W; von der Hardt H
Med Klin (Munich); 1995 Apr; 90(4):220-4. PubMed ID: 7776934
[TBL] [Abstract][Full Text] [Related]
45. Effect of DNase on exercise capacity in cystic fibrosis.
Barker M; Franke E; Böhle M; Pfannenstiel C; Heimann G
Pediatr Pulmonol; 2004 Jul; 38(1):70-4. PubMed ID: 15170876
[TBL] [Abstract][Full Text] [Related]
46. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis.
Suri R; Grieve R; Normand C; Metcalfe C; Thompson S; Wallis C; Bush A
Thorax; 2002 Oct; 57(10):841-6. PubMed ID: 12324668
[TBL] [Abstract][Full Text] [Related]
47. Gamma scintigraphic evaluation of a miniaturized AERx pulmonary delivery system for aerosol delivery to anesthetized animals using a positive pressure ventilation system.
Deshpande DS; Blanchard JD; Schuster J; Fairbanks D; Hobbs C; Beihn R; Densmore C; Farr S; Gonda I
J Aerosol Med; 2005; 18(1):34-44. PubMed ID: 15741772
[TBL] [Abstract][Full Text] [Related]
48. [Recombinant human DNase in conditions other than cystic fibrosis].
Kristensen K
Ugeskr Laeger; 2010 Feb; 172(8):616-9. PubMed ID: 20184817
[TBL] [Abstract][Full Text] [Related]
49. Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis.
Eng PA; Morton J; Douglass JA; Riedler J; Wilson J; Robertson CF
Pediatr Pulmonol; 1996 Feb; 21(2):77-83. PubMed ID: 8882210
[TBL] [Abstract][Full Text] [Related]
50. Use of computerized tomography and chest x-rays in evaluating efficacy of aerosolized recombinant human DNase in cystic fibrosis patients younger than age 5 years: a preliminary study.
Nasr SZ; Kuhns LR; Brown RW; Hurwitz ME; Sanders GM; Strouse PJ
Pediatr Pulmonol; 2001 May; 31(5):377-82. PubMed ID: 11340684
[TBL] [Abstract][Full Text] [Related]
51. Aerosolized dornase alfa (rhDNase) for therapy of cystic fibrosis.
Hodson ME
Am J Respir Crit Care Med; 1995 Mar; 151(3 Pt 2):S70-4. PubMed ID: 7881698
[TBL] [Abstract][Full Text] [Related]
52. Lung deposition after electronically breath-controlled inhalation and manually triggered conventional inhalation in cystic fibrosis patients.
Köhler E; Sollich V; Schuster-Wonka R; Jorch G
J Aerosol Med; 2005; 18(4):386-95. PubMed ID: 16379615
[TBL] [Abstract][Full Text] [Related]
53. [New pharmacological approaches: rhDNase].
Tournier G; Sardet A; Grosskopf C; Baculard A; Delaisi B
Rev Pneumol Clin; 1995; 51(3):193-200. PubMed ID: 7569583
[TBL] [Abstract][Full Text] [Related]
54. Effects of administration of aerosolized recombinant human deoxyribonuclease on resting energy expenditure in patients with cystic fibrosis.
Amin N; Dozor AJ
Pediatr Pulmonol; 1994 Sep; 18(3):150-4. PubMed ID: 7800431
[TBL] [Abstract][Full Text] [Related]
55. Dry powder inhalation versus wet nebulisation delivery of antibiotics in cystic fibrosis patients.
Westerman EM; Heijerman HG; Frijlink HW
Expert Opin Drug Deliv; 2007 Mar; 4(2):91-4. PubMed ID: 17335406
[TBL] [Abstract][Full Text] [Related]
56. Clinical benefit from nebulized human recombinant DNase in Kartagener's syndrome.
Desai M; Weller PH; Spencer DA
Pediatr Pulmonol; 1995 Nov; 20(5):307-8. PubMed ID: 8903903
[TBL] [Abstract][Full Text] [Related]
57. Nebulised bronchodilators, antibiotics and rhDNase for children with cystic fibrosis.
Spencer DA
Thorax; 1997 Apr; 52 Suppl 2(Suppl 2):S89-91. PubMed ID: 9155860
[No Abstract] [Full Text] [Related]
58. Aerosolized dornase alpha (rhDNase) in cystic fibrosis.
Bates RD; Nahata MC
J Clin Pharm Ther; 1995 Dec; 20(6):313-5. PubMed ID: 8847368
[TBL] [Abstract][Full Text] [Related]
59. A cost-effectiveness analysis of rhDNase in children with cystic fibrosis.
Grieve R; Thompson S; Normand C; Suri R; Bush A; Wallis C
Int J Technol Assess Health Care; 2003; 19(1):71-9. PubMed ID: 12701940
[TBL] [Abstract][Full Text] [Related]
60. In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis.
Shah PL; Scott SF; Knight RA; Marriott C; Ranasinha C; Hodson ME
Thorax; 1996 Feb; 51(2):119-25. PubMed ID: 8711640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
